OMNIX MEDICAL ADVANCES NOVEL ANTI-INFECTIVE PROGRAM INTO CLINICAL DEVELOPMENT
Entirely novel therapeutic principle to combat alarming worldwide rise of antimicrobial resistance (AMR) JERUSALEM, Israel, March 16, 2022 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced it received approval by Dutch authorities to initiate a Phase I clinical trial with its lead compound OMN6 in healthy […]
OMNIX MEDICAL CSO NAMED A BEAM ALLIANCE NATIONAL COORDINATOR
To encourage EU Member States to actively contribute to exchanges on AMR in the co-legislative process, the BEAM Alliance relies on a network of National Coordinators. The aim is to encourage every state to put in place their own plan to combat AMR, in particular by supporting innovation. Omnix Medical is pleased to share the work of […]
OMNIX EARNS GRANT AWARD FROM ISRAEL INNOVATION AUTHORITY
Omnix Medical is honored to have earned a recent grant award from the Israel Innovation Authority to support continued development of new and effective lifesaving drugs to combat the spread of antimicrobial resistance.
EUROPE’S ANTIBIOTIC INVESTMENTS STAGNATE AS RESISTANCE CRISIS LOOMS
By Jonathan Smith at Labiotech.eu Despite the urgent danger of antibiotic resistance, investments into European biotech antibiotic players have remained flat. However, growing regulatory and societal awareness could spell fresh investments in the coming years. Over the last decade, pressure has been mounting on healthcare systems as infectious microbes become harder and harder to fight […]
OMNIX MEDICAL RECEIVES NIH GRANT FOR THE DEVELOPMENT OF ITS NOVEL ANTIMICROBIAL PEPTIDE OMN6
Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB) Clinical trial preparations of OMN6 under way Jerusalem, Israel — Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has received a grant by the U.S. National Institutes of Health (NIH) for the development of its first-in-class antimicrobial peptide […]
OMN6 A NOVEL BIOENGINEERED PEPTIDE FOR THE TREATMENT OF MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIA
New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we present superior properties of an engineered antimicrobial peptide, OMN6, a 40‐amino acid cyclic peptide based on Cecropin A . . . READ ARTICLE PUBLISHED MARCH 23, 2021
OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII
Une nouvelle technologie inspirée par la nature pour éradiquer de dangereuses bactéries multirésistantes. (A new technology inspired by nature to eradicate dangerous multiresistant bacteria.)
COMPANY NEWS: OMNIX MEDICAL WINS €10.8M IN EIC ACCELERATOR FUNDING
Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme.
OMNIX MEDICAL ANNOUNCES SUCCESSFUL $8.5 MILLION FUNDING ROUND
Omnix Medical, a Jerusalem-based biopharmaceutical company, has completed an $8.5 million round led by Tal Capital (US) and Entrée Capital (IL) in association with UK based businessman Vincent Chenkwiz of CBG Group (UK) and joined by Xenia Ventures (IL) VLX Ventures (IL) and the Israeli Innovation Authority (IIA). Since its inception, the company has raised $10M.
OMNIX MEDICAL APPOINTS ANTONIUS SCHUH TO ITS BOARD OF DIRECTORS
Omnix Medical, a biotech company dedicated to the development of novel antimicrobial pharmaceuticals against drug-resistant bacteria, today announced the appointment of Antonius (Toni) Schuh, Ph.D., to its Board of Directors. Dr. Schuh is a Managing Partner of Global Source Ventures. He has over 20 years of executive leadership experience in the biotechnology, healthcare and life sciences […]
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).